● Recruiting

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Condition: Uterine Sarcoma · Uterine Leiomyosarcoma · Endometrial Stromal Sarcoma · Sponsor: Dana-Farber Cancer Institute

PhasePhase 2

Planned participants30

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersYes

About this study

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)

This description comes directly from the study's public registry record.

Talk to the study team

Suzanne George, MD · 617-632-5204 · suzanne_george@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07467772